This HTML5 document contains 69 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00919/identifier/pubchem-substance/
n11http://linked.opendata.cz/resource/drugbank/company/
n23http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00919/identifier/drugbank/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00919/identifier/national-drug-code-directory/
n10http://bio2rdf.org/drugbank:
n20http://linked.opendata.cz/resource/drugbank/drug/DB00919/identifier/chemspider/
admshttp://www.w3.org/ns/adms#
n8http://www.drugs.com/mtm/
n6http://www.rxlist.com/cgi/generic/
n24http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n22http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00919/identifier/wikipedia/
n4http://linked.opendata.cz/resource/drugbank/property/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00919/identifier/pharmgkb/
xsdhhttp://www.w3.org/2001/XMLSchema#
n16http://linked.opendata.cz/resource/drugbank/drug/DB00919/identifier/kegg-compound/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00919/identifier/pdb/
n17http://linked.opendata.cz/ontology/sukl/drug/
n18http://linked.opendata.cz/resource/atc/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00919/identifier/pubchem-compound/

Statements

Subject Item
n2:DB00919
rdf:type
n3:Drug
n3:description
An antibiotic produced by Streptomyces spectabilis. It is active against gram-negative bacteria and used for the treatment of gonorrhea.
n3:group
approved
n3:halfLife
1 to 3 hours in patients with normal renal function and 10 to 30 hours in patients with impaired renal function with a creatinine clearance < 20 mL per minute.
n3:indication
For use in the treatment of acute gonorrheal urethritis and proctitis in the male and acute gonorrheal cervicitis and proctitis in the female when due to susceptible strains of <i>Neisseria gonorrhoeae</i>.
n3:manufacturer
n11:271B608E-363D-11E5-9242-09173F13E4C5
owl:sameAs
n10:DB00919 n24:DB00919
dcterms:title
Spectinomycin
adms:identifier
n13:15541 n14:46505032 n15:SCM n16:C02078 n19:0009-0566-01 n20:14785 n21:DB00919 n25:Spectinomycin n26:PA164781342
n3:mechanismOfAction
Spectinomycin is an inhibitor of protein synthesis in the bacterial cell; the site of action is the 30S ribosomal subunit. It is bactericidal in its action.
n3:packager
n11:271B608C-363D-11E5-9242-09173F13E4C5 n11:271B608D-363D-11E5-9242-09173F13E4C5
n3:synonym
Spectinomycine Espectinomicina SCM Spectinomicina Actinospectacina Spectinomycinum Antibiotic 2233WP
n3:toxicity
Acute oral toxicity (LD<sub>50</sub>): >5000 mg/kg [Rat]. Information on overdosage in humans is not available.
n3:proteinBinding
Not significant
n3:salt
n3:synthesisReference
David R. White, "Intermediate compounds in the preparation of spectinomycin." U.S. Patent US4344882, issued August, 1966.
n22:hasConcept
n23:M0000292
foaf:page
n6:trobicin.htm n8:spectinomycin.html
n3:IUPAC-Name
n4:271B6093-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B6099-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B6098-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B6095-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B6096-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B6097-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B60A9-363D-11E5-9242-09173F13E4C5 n4:271B6091-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B60AA-363D-11E5-9242-09173F13E4C5 n4:271B608F-363D-11E5-9242-09173F13E4C5 n4:271B6092-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B6090-363D-11E5-9242-09173F13E4C5
n3:pKa
n4:271B60AB-363D-11E5-9242-09173F13E4C5
n17:hasATCCode
n18:J01XX04
n3:H-Bond-Acceptor-Count
n4:271B609F-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B60A0-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B609A-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B609B-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B609D-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B609C-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B609E-363D-11E5-9242-09173F13E4C5
n3:absorption
Rapidly and almost completely absorbed after intramuscular injection.
n3:affectedOrganism
Enteric bacteria and other eubacteria
n3:casRegistryNumber
1695-77-8
n3:category
n3:Bioavailability
n4:271B60A5-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B60A7-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B60A8-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B60A4-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B60A3-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B60A6-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B6094-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B60A1-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B60A2-363D-11E5-9242-09173F13E4C5